[HTML][HTML] Repurposing sertraline sensitizes non–small cell lung cancer cells to erlotinib by inducing autophagy
Lung cancer patients treated with tyrosine kinase inhibitors (TKIs) often develop resistance.
More effective and safe therapeutic agents are urgently needed to overcome TKI resistance …
More effective and safe therapeutic agents are urgently needed to overcome TKI resistance …
[HTML][HTML] Combining EGFR-TKI with SAHA overcomes EGFR-TKI-acquired resistance by reducing the protective autophagy in non-small cell lung cancer
P Cao, Y Li, R Shi, Y Yuan, H Gong, G Zhu… - Frontiers in …, 2022 - frontiersin.org
At present, lung cancer is the cancer with the highest mortality rate in the world. The
emergence of EGFR tyrosine kinase inhibitors (TKIs) has greatly improved the survival of …
emergence of EGFR tyrosine kinase inhibitors (TKIs) has greatly improved the survival of …
[HTML][HTML] MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer
D Yan, JM Huelse, D Kireev, Z Tan… - The Journal of …, 2022 - Am Soc Clin Investig
JCI - MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung
cancer Go to JCI Insight About Editors Consulting Editors For authors Publication ethics Alerts …
cancer Go to JCI Insight About Editors Consulting Editors For authors Publication ethics Alerts …
[HTML][HTML] YAP1 synergize with YY1 transcriptional co-repress DUSP1 to induce osimertinib resistant by activating the EGFR/MAPK pathway and abrogating autophagy …
Y Ning, H Zheng, Y Yang, H Zang, W Wang… - … Journal of Biological …, 2023 - ncbi.nlm.nih.gov
YAP1 is a well-known core effector of the Hippo pathway in tumors, but its potential role in
osimertinib resistance remained unexplored. Our study provides evidence that YAP1 acts as …
osimertinib resistance remained unexplored. Our study provides evidence that YAP1 acts as …
[HTML][HTML] The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib
Y Zou, YH Ling, J Sironi, EL Schwartz… - Journal of Thoracic …, 2013 - Elsevier
Introduction The epidermal growth factor receptor (EGFR) inhibitor erlotinib is much less
effective in non–small-cell lung cancer (NSCLC) tumors with wild-type EGFR, than in tumors …
effective in non–small-cell lung cancer (NSCLC) tumors with wild-type EGFR, than in tumors …
Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer
KR Zhang, YF Zhang, HM Lei, YB Tang… - Science translational …, 2021 - science.org
Acquired resistance represents a bottleneck to molecularly targeted therapies such as
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment in lung …
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment in lung …
Targeting acetylcholine signaling modulates persistent drug tolerance in EGFR-mutant lung cancer and impedes tumor relapse
M Nie, N Chen, H Pang, T Jiang… - The Journal of …, 2022 - Am Soc Clin Investig
Although first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
therapy is effective for treating EGFR-mutant non–small cell lung cancer (NSCLC), it is now …
therapy is effective for treating EGFR-mutant non–small cell lung cancer (NSCLC), it is now …
EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells
W Han, H Pan, Y Chen, J Sun, Y Wang, J Li, W Ge… - PloS one, 2011 - journals.plos.org
Epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib have been
widely used in patients with non-small-cell lung cancer. Unfortunately, the efficacy of EGFR …
widely used in patients with non-small-cell lung cancer. Unfortunately, the efficacy of EGFR …
miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma
WC Zhang, JM Wells, KH Chow, H Huang, M Yuan… - Nature …, 2019 - nature.com
Drug tolerance is an acute defence response preceding a fully drug-resistant state and
tumour relapse; however, there are few therapeutic agents targeting drug tolerance in the …
tumour relapse; however, there are few therapeutic agents targeting drug tolerance in the …
Protective autophagy decreases osimertinib cytotoxicity through regulation of stem cell-like properties in lung cancer
L Li, Y Wang, L Jiao, C Lin, C Lu, K Zhang, C Hu, J Ye… - Cancer Letters, 2019 - Elsevier
Osimertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI), shows great efficacy in EGFR-mutant non-small cell lung cancer (NSCLC); …
(EGFR-TKI), shows great efficacy in EGFR-mutant non-small cell lung cancer (NSCLC); …